Moderna

Moderna to present Phase 3 cancer vaccine data at ESMO

Moderna announced on Monday that late-breaking Phase 3 data for its personalized mRNA cancer therapy, intismeran autogene, will be presented at a Presidential Symposium during the European Society for Medical Oncology Congress 2026 in Madrid. The presentation is scheduled for…

Moderna eyes solo mRNA cancer vaccine, in vivo CAR-T after landmark trial

Moderna is widening its cancer drug pipeline after achieving the first positive Phase 3 result for an mRNA-based cancer treatment, a milestone the company is now leveraging to push into monotherapy vaccines, in vivo CAR-T cell therapy, and treatments targeting…

Study finds genes can combine to make unknown proteins

Researchers at Harvard Medical School have found that instructions from different genes — even those located on separate chromosomes — can combine to create chimeric mRNAs that produce previously unknown, functional proteins. The findings, published Wednesday in Nature Springer Nature…

Moderna shares surge after mRNA cancer vaccine clears Phase 3 trial

Moderna shares soared as much as 100% on Wednesday after the company and partner Merck announced that their personalized mRNA cancer vaccine met both primary goals in a pivotal late-stage melanoma trial — the first positive Phase 3 result ever…

Merck, Moderna mRNA cancer vaccine succeeds in Phase 3 trial

Merck and Moderna announced Wednesday that their personalized mRNA cancer vaccine succeeded in a Phase 3 clinical trial, marking the first late-stage positive readout for an individualized neoantigen therapy and for any mRNA-based cancer treatment.

WHO recommends testing existing Ebola vaccine against Bundibugyo strain in DRC

Moderna has launched the first human clinical trial of an mRNA vaccine targeting Bundibugyo ebolavirus, the strain driving a deadly outbreak in the Democratic Republic of the Congo that has now killed more than 2,100 people and for which no…

Moderna begins first human trial of Bundibugyo Ebola vaccine

Moderna announced Tuesday that it has begun dosing volunteers in the first human trial of mRNA-1469, an experimental vaccine targeting the Bundibugyo strain of Ebola virus — a pathogen with no approved vaccine that is fueling the second-largest Ebola outbreak…

Sanofi sues Pfizer, Moderna over COVID vaccine patents

Sanofi has filed federal lawsuits against both Moderna and Pfizer, alleging their COVID-19 vaccines infringe the French drugmaker's patents covering mRNA technology, according to Reuters.

US commits $50M to CEPI for Bundibugyo Ebola countermeasures

The United States announced a $50 million commitment to the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate development of medical countermeasures against the Bundibugyo strain of Ebola virus, as the deadly outbreak in the Democratic Republic of Congo continues…

Moderna’s mRNA cancer prevention vaccine wins UK approval for clinical trial

Moderna and the University of Oxford announced on June 8 that their Phase 1/2 trial of mRNA-4194, an investigational mRNA-based cancer vaccine targeting Lynch syndrome, has received authorization from the UK's Medicines and Healthcare products Regulatory Agency. The trial, called…